webinar register page

Webinar banner
Fireside Chat: VBI Vaccines (VBIV)
Please join RJ biotech Analyst Steve Seedhouse as he hosts VBI Vaccines CEO, Jeff Baxter, and Chief Scientific Officer, Dave Anderson, for a discussion of their hep B portfolio, including their prophylactic commercial program and new data from their immunotherapeutic to treat chronic HBV.

VBI Vaccines is a commercial-stage biopharmaceutical company focused on developing the next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing both the prevention and treatment of hepatitis B, with the only commercially approved 3-antigen hepatitis B vaccine, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], which is now approved for use in the U.S., European Union/European Economic Area, United Kingdom, Canada, and Israel. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI is developing vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is developing vaccine candidates to tackle significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, MA and has research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Hosted by Raymond James Biotech anlayst Steve Seedhouse | Steve.Seedhouse@RaymondJames.com


* Required information

All expressions of opinion reflect the judgment of the author(s) and are subject to change. This information should not be construed as a recommendation. The foregoing content is subject to change at any time without notice. Content provided herein is for informational purposes only. There is no guarantee that these statements, opinions or forecasts provided herein will prove to be correct. Economic and market conditions are subject to change. Raymond James & Associates, Inc., member New York Stock Exchange/SIPC.


Jeff Baxter
President and CEO
Mr. Baxter joined VBI in September of 2009. Previously, he was a managing partner for the venture capital firm, The Column Group. Until July of 2006, Mr. Baxter was SVP, R&D Finance and Operations, of GlaxoSmithKline (GSK). In his 19 years of pharma experience, he has held line management roles in commercial, manufacturing and IT and the office of the CEO. His most recent position in R&D included responsibility for finance, pipeline resource planning and allocation, business development deal structuring and SROne (GSK’s in-house $125m venture capital fund). He also chaired GSK’s R&D Operating Board. Prior to GSK, he worked at Unilever. Mr. Baxter was educated at Thames Valley University and is a Fellow of the Chartered Institute of Management Accountants (FCMA).
Dave Anderson
Chief Scientific Officer
A dynamic and well-published immunologist with broad expertise in the areas of vaccine development, autoimmunity and tumor immunology, Dr. Anderson joined VBI full time in 2009 from Harvard Medical School, where he held a position as Assistant Professor. As a co-founder and Chief Scientific Officer of VBI, Dr. Anderson is an inventor of much of the Company’s intellectual property and actively manages its ongoing expansion. Dr. Anderson holds a Ph.D. from Harvard University and a B.S. from the University of California at Davis.